The Oncologic Drugs Advisory Committee advises the US Food and Drug Administration (FDA) about medications for the treatment of cancer. The committee's meeting agenda typically includes presentations by both a company seeking marketing approval for an oncologic drug that it sponsors and by the FDA, as well as a public hearing for comments by other speakers. Speakers may be patients with cancer or may represent patient advocacy organizations, and speakers are asked to disclose financial associations with the sponsoring company or other relevant financial associations.
Prior research has examined the characteristics of decisions by the Oncologic Drugs Advisory Committee 1 and financial conflict of interest disclosures and voting patterns at FDA drug advisory committee meetings. 2 We studied the characteristics and financial associations of public speakers at meetings of the Oncologic Drugs Advisory Committee.
Methods | We identified all Oncologic Drugs Advisory Committee meetings from 2009 to 2014 (n = 49) and reviewed the published transcripts of the meetings at the FDA website. 3 The review was conducted from August 14 to August 23, 2015, and excluded meetings that did not have public hearings (n = 13) or did not discuss cancer drugs (n = 8) (eg, supportive medications were discussed). We documented whether speakers reported having cancer, having taken the medication for which approval was being sought, represented an organization, and had a relevant financial association and, if so, the nature of that financial association (eg, receiving travel fees). We classified speakers' comments as favorable, neutral, or negative toward marketing approval. The study was an investigation of published reports and, according to Department of Health and Human Services regulations, was exempt from institutional review board approval.
Results | Table 1 shows the 28 Oncologic Drugs Advisory Committee meetings that met our inclusion criteria. We identified drug was used ( Table 2) . Thirty-one speakers (30.1%) reported financial associations, such as support for travel to the meeting (n = 11) or the organization they represented received support from the pharmaceutical company that was seeking marketing approval (n = 18), or received both travel funds and organizational support (n = 2). Two speakers reported serving as principal investigators of pivotal trials of the drug. Two individuals disclosed organizational affiliations but not financial associations, and subsequent searches of online information showed that the specified organizations had received financial support from the sponsor before the meeting. Of the speakers, 95 (92.2%) supported marketing approval, 6 (5.8%) did not (none of whom reported a financial association with the sponsoring company), and 2 (1.9%) were neutral.
Discussion | Public speakers at meetings of the Oncologic Drugs Advisory Committee can offer unique perspectives not represented by the sponsor of a drug, the FDA, or panel members of the Oncologic Drugs Advisory Committee. Some have the cancer in question or have taken the investigational drug. However, many speakers at these meetings also have financial associations with the company seeking marketing approval or represent an organization that receives financial support from the company. In 2 instances, we found that financial associations were not disclosed. The characteristics of the public speakers at these meetings should be kept in mind as their comments are considered. Future investigations should explore the Most of the financial ties were disclosed, but not all. It is understandably challenging to attract public speakers without vested interests to undertake the time, travel, and expense involved in attending a federal health advisory committee meeting. At such meetings, these speakers often tell anecdotal stories that, although informative, require evaluation in the evidence-based framework that is an essential part of advisory committee deliberations. The analysis by Abola and Prasad 1 also suggests that advisory committee members and federal health officials should recognize that public speakers represent a nonrepresentative sample of speakers who may be biased toward a favorable view of the drug or medical device that is being discussed. Comments by patients and public speakers are valuable at federal health advisory committee meetings. They offer an additional perspective to those of the patient representatives, in the case of the FDA, and patient advocates, in the case of the Medicare Evidence Development and Coverage Advisory Committee, who serve as members of the committees. A more robust selection system, however, would improve the objectivity and range of input to the FDA and CMS panels that conduct the agencies' health advisory committee meetings. The FDA has recently initiated new programs to engage patients and to incorporate patient perspectives into its regulatory evaluations and decision-making.
2 The FDA, CMS, and other federal health agencies should supplement public comments with systematic information about patient perspectives on medical products and patient-reported outcomes of their use.
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